Intervention

Abraxane

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 32 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials32

Recruiting3

Common conditions25

Lead sponsors shown15

Clinical trials

32 shown

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard TherapyNCT07284836 · 2025-02-01

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.NCT07394387 · 2025-01-01

Abequolixron (RGX-104) and Durvalumab in Lung CancerNCT05911308 · 2024-04-01

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisNCT04639271 · 2021-01-01

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaNCT03361319 · 2020-07-01

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerNCT03950570 · 2019-05-25

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerNCT03647514 · 2018-12-01

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerNCT03647280 · 2018-12-01

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast CancerNCT02687490 · 2017-02-24

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1NCT02620280 · 2016-04-01

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung CancerNCT02662634 · 2016-03-01

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based ChemotherapyNCT02303977 · 2015-06-26

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL CancerNCT02328105 · 2014-12-01

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerNCT01938833 · 2014-04-01

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelNCT02073487 · 2014-02-01

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerNCT02073916 · 2013-10-01

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast CancerNCT01822314 · 2013-04-01

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast CancerNCT01647672 · 2012-01-01

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)NCT01446016 · 2011-09-01

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast CancerNCT01207102 · 2011-08-01

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast CancerNCT00821964 · 2008-12-01

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast CancerNCT00723125 · 2008-09-01

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate CancerNCT00521781 · 2007-08-01

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast CancerNCT00503906 · 2007-06-01

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast CancerNCT00479674 · 2007-05-01

Abraxane and Alimta in Advanced Solid TumorsNCT00470548 · 2007-04-01

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast CancerNCT00442260 · 2007-02-01

Study of Abraxane and Carboplatin to Treat Small Cell Lung CancerNCT00454324 · 2006-04-01

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast CancerNCT00308178 · 2006-03-01

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate CancerNCT00284752 · 2005-08-01

Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast CancerNCT00107094 · 2005-03-01

Common conditions

Leading sponsors

The Methodist Hospital Research Institute 3 Zhejiang Cancer Hospital 3 Duke University 2 Fondazione Michelangelo 2 UNC Lineberger Comprehensive Cancer Center 2 Abramson Cancer Center at Penn Medicine 1 Celgene Corporation 1 Fudan University 1 GU Research Network, LLC 1 H. Lee Moffitt Cancer Center and Research Institute 1 Harold J. Burstein, MD, PhD 1 Jenny C. Chang, MD 1 Kaiser Permanente 1 Orinove, Inc. 1 Royal Marsden NHS Foundation Trust 1

Trial status mix

COMPLETED17

TERMINATED6

UNKNOWN4

RECRUITING3

WITHDRAWN2

Phase mix

PHASE224

PHASE18

NA3

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.